1. Home
  2. SKYE vs SNT Comparison

SKYE vs SNT Comparison

Compare SKYE & SNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • SNT
  • Stock Information
  • Founded
  • SKYE 2012
  • SNT 1965
  • Country
  • SKYE United States
  • SNT Canada
  • Employees
  • SKYE N/A
  • SNT N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • SNT Telecommunications Equipment
  • Sector
  • SKYE Health Care
  • SNT Telecommunications
  • Exchange
  • SKYE Nasdaq
  • SNT Nasdaq
  • Market Cap
  • SKYE 115.9M
  • SNT 95.2M
  • IPO Year
  • SKYE N/A
  • SNT 1993
  • Fundamental
  • Price
  • SKYE $3.98
  • SNT $4.63
  • Analyst Decision
  • SKYE Buy
  • SNT
  • Analyst Count
  • SKYE 6
  • SNT 0
  • Target Price
  • SKYE $16.60
  • SNT N/A
  • AVG Volume (30 Days)
  • SKYE 2.2M
  • SNT 117.1K
  • Earning Date
  • SKYE 08-08-2025
  • SNT 08-25-2025
  • Dividend Yield
  • SKYE N/A
  • SNT N/A
  • EPS Growth
  • SKYE N/A
  • SNT N/A
  • EPS
  • SKYE N/A
  • SNT 0.18
  • Revenue
  • SKYE N/A
  • SNT $36,690,000.00
  • Revenue This Year
  • SKYE N/A
  • SNT N/A
  • Revenue Next Year
  • SKYE N/A
  • SNT N/A
  • P/E Ratio
  • SKYE N/A
  • SNT $26.06
  • Revenue Growth
  • SKYE N/A
  • SNT 8.36
  • 52 Week Low
  • SKYE $1.14
  • SNT $1.40
  • 52 Week High
  • SKYE $7.47
  • SNT $5.04
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 60.88
  • SNT 57.67
  • Support Level
  • SKYE $3.65
  • SNT $4.60
  • Resistance Level
  • SKYE $4.75
  • SNT $4.92
  • Average True Range (ATR)
  • SKYE 0.71
  • SNT 0.29
  • MACD
  • SKYE 0.00
  • SNT -0.01
  • Stochastic Oscillator
  • SKYE 48.55
  • SNT 52.70

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About SNT Senstar Technologies Ltd.

Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.

Share on Social Networks: